| Name | BMS493 |
| Description | BMS493 is an inverse agonist of the pan-retinoic acid receptor (RAR) that inhibits retinoic acid-induced differentiation, enhances the interaction of nuclear co-inhibitors with RARs, attenuates RA signaling, potentiates TPP-induced toxicity, and inhibits the increase in phospholipase A2 activity. |
| In vitro | Cells treated with BMS 493 (100 nM; 6 days) showed a twofold increase in the number of ALDHhi cells available for transplantation compared to untreated controls. Newly expanded ALDHhi cells exhibited increased numbers of CD34 and CD133-positive cells, along with a reduction in CD38 expression[1]. |
| In vivo | In contrast to freshly isolated ALDHhi cells, 6-day expansion with or without BMS 493 generated progeny that were unable to reduce hyperglycemia after iPan transplantation into STZ-treated NOD/SCID mice[1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5.5 mg/mL (13.6 mM), Suspension.
10% DMSO+90% Saline : < 5.5 mg/mL (13.6 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
DMSO : 55 mg/mL (135.97 mM), Sonication is recommended.
|
| Keywords | RetinoidReceptor | Retinoid Receptor | RAR | phospholipase A2 | BMS493 | BMS 493 |
| Inhibitors Related | Neomycin sulfate | Isotretinoin | Levamisole hydrochloride | 1,3,5-Triisopropylbenzene | Retinoic acid | Difluprednate | trans-Benzylideneacetone | Indomethacin | 2,4-Di-tert-butylphenol | Lansoprazole | Magnolol | Magnesium sulfate |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Bioactive Compounds Library Max |
United States
